PCN120 - A Cost-Effectiveness Analysis (CEA) Of Cetuximab+Folfiri Compared to Bevacizumab+Folfiri as First-Line Treatment of Ras Wild-Type (WT) Metastatic Colorectal Cancer (MCRC): A US Analysis Based on Location of Primary Tumor

Autor: Evans, R, Aggarwal, H, Takundwa, R, Chin, S, Fenwick, E
Zdroj: In Value in Health May 2018 21 Supplement 1:S31-S31
Databáze: ScienceDirect
Externí odkaz: